Your browser is no longer supported. Please, upgrade your browser.
NEW! We've added Bitcoin charts to our Forex section. ×
Settings
GILD [NASD]
Gilead Sciences Inc.
IndexS&P 500 P/E12.69 EPS (ttm)8.80 Insider Own0.50% Shs Outstand1.47B Perf Week2.20%
Market Cap164.17B Forward P/E10.13 EPS next Y11.02 Insider Trans-18.42% Shs Float1.46B Perf Month6.18%
Income14.21B PEG0.95 EPS next Q2.66 Inst Own85.60% Short Float3.80% Perf Quarter6.89%
Sales27.49B P/S5.97 EPS this Y306.10% Inst Trans-1.84% Short Ratio5.18 Perf Half Y9.16%
Book/sh11.55 P/B9.67 EPS next Y1.56% ROA42.70% Target Price121.22 Perf Year34.75%
Cash/sh7.69 P/C14.54 EPS next 5Y13.30% ROE91.30% 52W Range78.50 - 116.83 Perf YTD18.51%
Dividend1.72 P/FCF9.99 EPS past 5Y39.10% ROI44.80% 52W High-4.38% Beta0.75
Dividend %1.54% Quick Ratio2.40 Sales past 5Y28.80% Gross Margin86.00% 52W Low42.31% ATR2.32
Employees7000 Current Ratio2.70 Sales Q/Q51.90% Oper. Margin64.00% RSI (14)69.02 Volatility1.80% 2.16%
OptionableYes Debt/Eq0.72 EPS Q/Q107.50% Profit Margin51.70% Rel Volume1.13 Prev Close111.22
ShortableYes LT Debt/Eq0.69 EarningsApr 30 AMC Payout4.60% Avg Volume10.71M Price111.71
Recom1.90 SMA205.76% SMA508.58% SMA2008.56% Volume12,075,190 Change0.44%
May-01-15Reiterated RBC Capital Mkts Outperform $118 → $120
May-01-15Reiterated Piper Jaffray Overweight $116 → $120
Feb-04-15Reiterated RBC Capital Mkts Outperform $125 → $118
Dec-23-14Reiterated Deutsche Bank Buy $142 → $125
Dec-09-14Reiterated Argus Buy $110 → $130
Oct-29-14Reiterated RBC Capital Mkts Outperform $115 → $125
Oct-13-14Reiterated FBR Capital Outperform $125 → $130
Sep-25-14Reiterated Needham Buy $95 → $120
Aug-22-14Reiterated RBC Capital Mkts Outperform $102 → $115
Aug-15-14Initiated FBR Capital Outperform $125
Aug-11-14Reiterated Argus Buy $90 → $110
Jul-28-14Reiterated Maxim Group Buy $112 → $127
Jul-24-14Reiterated RBC Capital Mkts Outperform $96 → $102
Apr-28-14Reiterated Maxim Group Buy $101 → $112
Feb-21-14Reiterated Barclays Overweight $90 → $95
Feb-10-14Reiterated Argus Buy $84 → $90
Feb-05-14Reiterated RBC Capital Mkts Outperform $90 → $96
Feb-05-14Reiterated Needham Buy $85 → $95
Feb-05-14Reiterated Maxim Group Buy $98 → $101
Feb-04-14Upgrade Robert W. Baird Neutral → Outperform $65 → $103
May-25-15 02:00PM  Bristol-Myers' Opdivo Gets Positive Opinion from CHMP - Analyst Blog
01:01AM  FireEye, Gilead Sciences, and Aeropostale: Doug Kass' Views
May-24-15 09:15AM  Large Companies With Fastest Revenue and Earnings Growth in 2015 at 24/7 Wall St.
May-23-15 10:00AM  Can Gilead keep growing without a big deal? at Fortune
09:30AM  The Most Loved Biotechs of Big Hedge Funds at 24/7 Wall St.
06:32AM  The best blue chips to own forever at USA TODAY
May-22-15 09:02PM  Will This Drug Beat Gilead to Market in NASH? at Investopedia
04:40PM  Medical cost inflation hits 8-year high, but why? at CNBC
11:30AM  Kite Pharma Starts Dosing in Phase I/II Study on KTE-C19 - Analyst Blog
11:21AM  Gilead Sciences: Hep-C Prescriptions Continue to Fall at Barrons.com
08:49AM  Should You Get Rid of CytRx Corporation (CYTR) Now? - Tale of the Tape
08:11AM  Who are Gilead Sciences' (GILD) main competitors? at Investopedia
May-21-15 03:50PM  J&J (JNJ) to File for More than 10 New Products by 2019 - Analyst Blog
02:18PM  Why Do Biotech Stocks Look Attractive?
08:27AM  What Does The Johnson & Johnson/Achillion Deal Mean For HCV Competitors?
May-20-15 04:22PM  Will the J&J Deal With Achillion Transform the Hep C Market? at The Wall Street Journal
02:50PM  Top 10 stocks of the David Letterman era
01:52PM  Achillion Dives As J&J Hep C Deal Chills Buyout Buzz at Investor's Business Daily
12:44PM  Gilead Sciences Inc. (GILD), Yahoo! Inc. (YHOO) and Sinclair Broadcast Group Inc. (SBGI) Among the Top Picks of Bernard Selz at Insider Monkey
12:17PM  Gilead patents on costly hepatitis C drug challenged in 5 countries
12:00PM  Soaring Cash Makes Gilead Cheaper Than You Think at Investopedia
11:44AM  UPDATE 1-Achillion partners with J&J to develop hep C drugs (May 19)
10:50AM  High Price for Gilead Sciences Hep C Drug Prompts Patent Challenges at The Wall Street Journal
09:46AM  Gilead Sciences: Little Risk From Achillion's Hep-C Partnership With J&J at Barrons.com
09:34AM  Move Over Chip Stocks: Here Are 5 Top Biotechs at Investor's Business Daily
09:08AM  10 S&P 500 Companies to Have the Biggest Profit Growth in 2015 at TheStreet
08:45AM  Intercept Pharmaceuticals (ICPT) in Focus: Stock Tanks 16.1% - Tale of the Tape
May-19-15 05:34PM  Momentum bargain stocks: TSLA & more
05:07PM  Achillion, J&J To Jointly Develop Hepatitis C Drugs at Investor's Business Daily
04:51PM  Healthcare Winners and Losers: May 19, 2015
02:00PM  Lannett (LCI) Signs Deal to Acquire Silarx Pharmaceuticals - Analyst Blog
01:50PM  Celgene/Accelreon's Luspatercept Granted Fast Track Status - Analyst Blog
09:34AM  Jim Cramer -- Stock Market's Takeover Frenzy Won't End Anytime Soon at TheStreet
08:39AM  Eleven Biotherapeutics (EBIO) in Focus: Stock Tanks 69.2% - Tale of the Tape
08:33AM  3 Best Biotech Stocks to Add to Your Portfolio at TheStreet
06:28AM  Gilead Sciences Buying Achillion Was Twitter Speculation at Its Finest at TheStreet
May-18-15 06:44PM  5 Things Gilead Sciences Wants You to Know at Investopedia
05:00PM  Gilead Sciences to Present at the UBS 2015 Global Healthcare Conference on Tuesday, May 19 Business Wire
01:29PM  Jim Cramer -- St. Jude, Home Depot Lead Stocks in Second-Strongest Sectors at TheStreet
12:32PM  15 Years Later: A Look At The Nasdaq Composite Then and Now at Forbes
08:42AM  Gilead Sciences (GILD) Stock: 3 Reasons Why It Is a Top Choice for Growth Investors - Tale of the Tape
08:03AM  Is the Stock Market Due for a Correction?
07:39AM  How to play weak Q2 earnings season: Analysts at CNBC
May-15-15 06:13PM  Health Care Sector Delivers Healthy Q1 Results at Investor's Business Daily
03:35PM  Agenus (AGEN) Provides Update on its Brain Cancer Vaccine - Analyst Blog
01:40PM  Eli Lilly, Sanford-Burnham Ink Deal for Immunotherapies - Analyst Blog
01:04PM  GILEAD SCIENCES INC Financials
12:25PM  Dalio's Bridgewater Dramatically Adds to Apple, Cuts Gilead at Barrons.com
11:34AM  Gilead: Hep-C Prescriptions Fall, But Quarter Tracking Higher at Barrons.com
11:26AM  Prestige Brands Holdings Beats on Q4 Earnings, Revenues - Analyst Blog
May-14-15 02:07PM  Biotech: Asco Giveth, Asco Taketh Away at Barrons.com
01:52PM  What the travails of the UK's largest grocer can teach the pharmaceutical industry at Forbes
07:00AM  Biotech Fans Could Have a Hangover at Morningstar
12:37AM  Vertex Could Give Investors Vertigo at The Wall Street Journal
May-13-15 02:55PM  Retail Sector in the Spotlight - Earnings Trends
02:55PM  Retail Sector in the Spotlight - Earnings Outlook
02:40PM  Gilead: No Big Deals at Barrons.com
01:52PM  How much do Americans spend on drugs?
12:40PM  Vertex Pharmaceuticals' Orkambi Wins FDA Panel Backing - Analyst Blog
10:56AM  Biotech Stock Roundup: Alexion to Buy Synageva, FDA Panel Backs Vertex's Orkambi - Analyst Blog
10:52AM  Vertex Could Give Investors Vertigo at The Wall Street Journal
09:53AM  Gilead Sciences: Hep-C Prcing in Japan Better Than Expected at Barrons.com
09:47AM  Gilead Sciences, Inc. (GILD), Infoblox Inc (BLOX) Among David Lamonds Top Healthcare and Technology Stock Picks at Insider Monkey
12:01AM  500,000 Americans spend $50K on medicine each year at CNBC
12:00AM  Drug Costs Top $50K A Year For Half Million Americans at Forbes
May-12-15 06:34PM  Sanders Asks VA to Break Patents on Gilead and AbbVie Hep C Drugs at The Wall Street Journal
06:34PM  The Most Important Number for Gilead Shareholders at Investopedia
05:44PM  FDA panel approves Vertex drug
05:00PM  Gilead Sciences to Present at the Bank of America Merrill Lynch 2015 Health Care Conference on Wednesday, May 13 Business Wire
09:46AM  TrovaGene (TROV) in Focus: Stock Rises 7.1% - Tale of the Tape
09:20AM  Inovio Narrows Q1 Loss Y/Y, Misses Earnings Estimates - Analyst Blog
08:05AM  Short Sellers Start to Get Nervous on Biotech at 24/7 Wall St.
May-11-15 12:39PM  Gilead Leads HCV Race Despite Competition From AbbVie
12:22PM  ETFs in Focus on Impressive Q1 Biotech Earnings - ETF News And Commentary
10:10AM  Osiris Therapeutics Q1 Earnings & Revenues Grow Y/Y - Analyst Blog
09:26AM  Bio-Techne Lags on Q3 Earnings, Revenues; Expenses Rise - Analyst Blog
09:11AM  Seattle Genetics (SGEN) in Focus: Stock Up 8.1% - Tale of the Tape
May-10-15 08:11PM  10-Q for Gilead Sciences, Inc. at Company Spotlight
11:00AM  These biotech names are ripe for mergers: Analysts at CNBC
May-09-15 10:49AM  The Best And Worst ETFs Of The Week Amid Biotech Rebound
May-08-15 02:53PM  GILEAD SCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of
01:00PM  Corcept Therapeutics Reports Wider Q1 Loss, Revenue Miss - Analyst Blog
12:56PM  Gilead Sciences: How Are Hepatitis C Prescriptions Holding Up? at Barrons.com
11:50AM  Alnylam's Q1 Loss Narrower than Expected, Confirms Guidance - Analyst Blog
09:30AM  Zacks Earnings Trends Highlights: Walgreen Boots, Amazon and Gilead Sciences - Press Releases
06:16AM  WHO adds hepatitis C drugs to essential list, urges lower prices
May-07-15 02:49PM  Standout Sectors of Q1 Earnings Season - Earnings Trends
01:55PM  Sucampo Posts In-Line First-Quarter Earnings, Revenue Miss - Analyst Blog
May-06-15 05:55PM  Gilead Sciences Execs Sell $19 Million in Stock at Barrons.com
02:40PM  Synageva BioPharma: Another Winning Lottery Ticket For Investors at Forbes
09:30AM  Gilead's John C. Martin: One Breakthrough Drug After Another at Forbes
09:03AM  Gilead to Buy EpiTherapeutics for $65 Million at The Wall Street Journal
08:49AM  Gilead Sciences Acquires EpiTherapeutics at noodls
08:30AM  Gilead Sciences Acquires EpiTherapeutics Business Wire
06:12AM  Global 2000: Hall Of Fame CEOs On Growth, Good Advice And The Next Decade at Forbes
May-05-15 05:28PM  Gilead's Price Cuts Cause Hep C Scripts to Soar at Investopedia
01:16PM  Healthcare Mid-Day Winners and Losers: May 05, 2015
12:51PM  Healthcare AM Winners and Losers: May 05, 2015
12:46PM  Healthcare AM Winners and Losers: May 04, 2015
12:46PM  Healthcare Mid-Day Winners and Losers: May 04, 2015
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical nee in North America, South America, Europe, and the Asia-Pacific. The company's products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with Bristol-Myers Squibb Company', Janssen R&D Ireland, and Japan Tobacco Inc. to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Carter Paul RutherfordEVP Commercial OpsMay 15Option Exercise67.786,000406,68753,632May 19 07:24 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMay 15Option Exercise21.3470,0001,493,550235,168May 19 07:25 PM
Alton Gregg HEVP, Corp & Med AffairsMay 15Option Exercise19.2025,000479,947168,422May 19 07:25 PM
Carter Paul RutherfordEVP Commercial OpsMay 15Sale110.006,000660,02047,632May 19 07:24 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMay 15Sale109.4570,0007,661,533165,168May 19 07:25 PM
Alton Gregg HEVP, Corp & Med AffairsMay 15Sale110.0125,0002,750,210143,422May 19 07:25 PM
Carter Paul RutherfordEVP Commercial OpsMay 10Option Exercise0.005,000050,439May 12 06:02 PM
MILLIGAN JOHN FPresident and COOMay 07Option Exercise14.50100,0001,450,2501,129,108May 11 08:24 PM
MILLIGAN JOHN FPresident and COOMay 07Sale101.00100,00010,100,1621,029,108May 11 08:24 PM
Whitley Richard JamesDirectorMay 05Option Exercise19.6321,720426,36437,361May 07 05:14 PM
Carter Paul RutherfordEVP Commercial OpsMay 01Option Exercise80.652,000161,30047,439May 05 04:23 PM
MARTIN JOHN CChairman and CEOMay 01Option Exercise14.50150,0002,175,3754,405,876May 05 05:47 PM
Washington Robin LEVP, CFOMay 01Option Exercise29.7016,842500,13044,566May 05 07:38 PM
Alton Gregg HEVP, Corp & Med AffairsMay 01Option Exercise19.0910,000190,850155,422May 05 07:38 PM
Washington Robin LEVP, CFOMay 01Sale105.0616,8421,769,40527,724May 05 07:38 PM
MARTIN JOHN CChairman and CEOMay 01Sale104.95150,00015,742,4914,255,876May 05 05:47 PM
Carter Paul RutherfordEVP Commercial OpsMay 01Sale103.182,000206,36545,439May 05 04:23 PM
Alton Gregg HEVP, Corp & Med AffairsMay 01Sale104.0712,0001,248,871143,422May 05 07:38 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOApr 15Option Exercise20.7470,0001,451,800235,168Apr 17 02:23 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOApr 15Sale103.8470,0007,268,627165,168Apr 17 02:23 PM
Alton Gregg HEVP, Corp & Med AffairsApr 08Option Exercise19.095,00095,425150,422Apr 09 04:40 PM
Carter Paul RutherfordEVP Commercial OpsApr 08Option Exercise80.651,00080,65046,439Apr 09 04:40 PM
Alton Gregg HEVP, Corp & Med AffairsApr 08Sale100.005,000500,000145,422Apr 09 04:40 PM
Carter Paul RutherfordEVP Commercial OpsApr 08Sale100.001,000100,00045,439Apr 09 04:40 PM
Carter Paul RutherfordEVP Commercial OpsApr 01Option Exercise80.651,00080,65046,439Apr 03 05:24 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Option Exercise19.095,00095,425152,422Apr 03 05:24 PM
MARTIN JOHN CChairman and CEOApr 01Option Exercise14.50150,0002,175,3754,405,876Apr 03 05:24 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Sale96.537,000675,715145,422Apr 03 05:24 PM
Carter Paul RutherfordEVP Commercial OpsApr 01Sale98.041,00098,04445,439Apr 03 05:24 PM
MARTIN JOHN CChairman and CEOApr 01Sale96.74150,00014,511,4634,255,876Apr 03 05:24 PM
Whitley Richard JamesDirectorMar 02Option Exercise26.995,000134,95020,641Mar 03 04:12 PM
Alton Gregg HEVP, Corp & Med AffairsMar 02Option Exercise19.0910,000190,850159,422Mar 04 07:49 PM
MARTIN JOHN CChairman and CEOMar 02Option Exercise14.50150,0002,175,3754,405,876Mar 04 07:48 PM
Carter Paul RutherfordEVP Commercial OpsMar 02Option Exercise80.652,000161,30047,439Mar 04 07:49 PM
MARTIN JOHN CChairman and CEOMar 02Sale103.51150,00015,526,2454,255,876Mar 04 07:48 PM
Alton Gregg HEVP, Corp & Med AffairsMar 02Sale103.6312,0001,243,615147,422Mar 04 07:49 PM
Carter Paul RutherfordEVP Commercial OpsMar 02Sale104.182,000208,36445,439Mar 04 07:49 PM
Whitley Richard JamesDirectorMar 02Sale103.435,000517,13615,641Mar 03 04:12 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOFeb 17Option Exercise16.4070,0001,147,650235,168Feb 19 06:42 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOFeb 17Sale103.0170,0007,210,740165,168Feb 19 06:42 PM
WOLD OLSEN PERDirectorFeb 06Buy99.9210,000999,15088,173Feb 10 04:30 PM
MARTIN JOHN CChairman and CEOFeb 02Option Exercise14.50150,0002,175,3754,272,987Feb 04 08:15 PM
Washington Robin LEVP, CFOFeb 02Option Exercise25.1433,192834,58683,024Feb 04 08:52 PM
Alton Gregg HEVP, Corp & Med AffairsFeb 02Option Exercise19.0910,000190,850123,694Feb 04 08:51 PM
Carter Paul RutherfordEVP Commercial OpsFeb 02Option Exercise80.652,000161,30036,308Feb 04 08:52 PM
Whitley Richard JamesDirectorFeb 02Option Exercise26.995,000134,95020,641Feb 04 04:04 PM
MARTIN JOHN CChairman and CEOFeb 02Sale105.43150,00015,815,2494,122,987Feb 04 08:15 PM
Washington Robin LEVP, CFOFeb 02Sale105.3833,1923,497,66249,832Feb 04 08:52 PM
Alton Gregg HEVP, Corp & Med AffairsFeb 02Sale105.7312,0001,268,719111,694Feb 04 08:51 PM
Carter Paul RutherfordEVP Commercial OpsFeb 02Sale106.152,000212,31034,308Feb 04 08:52 PM
Whitley Richard JamesDirectorFeb 02Sale105.675,000528,35815,641Feb 04 04:04 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJan 15Option Exercise16.4070,0001,147,650189,302Jan 20 12:46 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJan 15Sale98.4770,0006,893,083119,302Jan 20 12:46 PM
Carter Paul RutherfordEVP Commercial OpsJan 08Option Exercise36.721,00036,72035,308Jan 12 03:55 PM
Carter Paul RutherfordEVP Commercial OpsJan 08Sale100.881,000100,88134,308Jan 12 03:55 PM
MARTIN JOHN CChairman and CEOJan 05Sale96.651009,6654,122,987Jan 06 04:20 PM
Whitley Richard JamesDirectorJan 02Option Exercise26.995,000134,95020,641Jan 06 02:12 PM
Carter Paul RutherfordEVP Commercial OpsJan 02Option Exercise40.561,00040,56035,308Jan 06 04:21 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Option Exercise19.095,00095,425120,694Jan 06 04:20 PM
MARTIN JOHN CChairman and CEOJan 02Option Exercise14.50150,0002,175,3754,272,987Jan 06 04:20 PM
MARTIN JOHN CChairman and CEOJan 02Sale95.11149,90014,257,7224,123,087Jan 06 04:20 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Sale95.177,000666,192113,694Jan 06 04:20 PM
Whitley Richard JamesDirectorJan 02Sale95.225,000476,10015,641Jan 06 02:12 PM
Carter Paul RutherfordEVP Commercial OpsJan 02Sale95.051,00095,05034,308Jan 06 04:21 PM
Cogan John FrancisDirectorDec 22Option Exercise14.3426,000372,77568,405Dec 24 12:58 PM
Cogan John FrancisDirectorDec 22Sale95.0326,0002,470,75542,405Dec 24 12:58 PM
MILLIGAN JOHN FPresident and COODec 08Option Exercise8.01146,8231,175,3181,120,871Dec 10 05:32 PM
MILLIGAN JOHN FPresident and COODec 08Sale106.26146,82315,601,122974,048Dec 10 05:32 PM
MARTIN JOHN CChairman and CEODec 01Option Exercise8.01140,6331,125,7674,263,620Dec 03 07:13 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Option Exercise40.562,00081,12036,308Dec 03 07:14 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Option Exercise24.2931,000752,947149,694Dec 03 07:13 PM
Whitley Richard JamesDirectorDec 01Option Exercise26.995,000134,95020,641Dec 03 03:46 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Sale100.022,000200,03134,308Dec 03 07:14 PM
MARTIN JOHN CChairman and CEODec 01Sale100.72140,63314,164,8294,122,987Dec 03 07:13 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Sale100.7933,0003,325,922116,694Dec 03 07:13 PM
Whitley Richard JamesDirectorDec 01Sale100.195,000500,96915,641Dec 03 03:46 PM
Cogan John FrancisDirectorNov 21Option Exercise14.3425,000358,43867,405Nov 25 04:10 PM
Cogan John FrancisDirectorNov 21Sale101.2325,0002,530,77042,405Nov 25 04:10 PM
MILLIGAN JOHN FPresident and COONov 07Option Exercise8.01146,8951,175,8941,120,943Nov 12 12:48 PM
MILLIGAN JOHN FPresident and COONov 07Sale107.37146,89515,772,736974,048Nov 12 12:48 PM
Washington Robin LEVP, CFONov 05Option Exercise0.006,000055,832Nov 07 01:20 PM
Carter Paul RutherfordEVP Commercial OpsNov 04Option Exercise0.004,800037,044Nov 05 05:37 PM
Whitley Richard JamesDirectorNov 03Option Exercise26.995,000134,95020,641Nov 05 12:23 PM
MARTIN JOHN CChairman and CEONov 03Option Exercise8.01140,6251,125,7034,570,012Nov 05 02:05 PM
Carter Paul RutherfordEVP Commercial OpsNov 03Option Exercise40.563,000121,68035,244Nov 05 05:37 PM
Washington Robin LEVP, CFONov 03Option Exercise25.1433,192834,58683,024Nov 05 08:06 PM
Carter Paul RutherfordEVP Commercial OpsNov 03Sale112.463,000337,38032,244Nov 05 05:37 PM
MARTIN JOHN CChairman and CEONov 03Sale110.40140,62515,525,1024,429,387Nov 05 02:05 PM
Whitley Richard JamesDirectorNov 03Sale112.025,000560,09015,641Nov 05 12:23 PM
Washington Robin LEVP, CFONov 03Sale110.2633,1923,659,83749,832Nov 05 08:06 PM
Carter Paul RutherfordEVP Commercial OpsOct 24Option Exercise40.562,00081,12034,244Oct 28 01:35 PM
Carter Paul RutherfordEVP Commercial OpsOct 24Sale110.002,000220,00732,244Oct 28 01:35 PM
Cogan John FrancisDirectorOct 21Option Exercise14.3415,000215,06357,405Oct 23 01:54 PM
Cogan John FrancisDirectorOct 21Sale104.0815,0001,561,14942,405Oct 23 01:54 PM
MILLIGAN JOHN FPresident and COOOct 07Option Exercise8.01146,8951,175,8941,120,943Oct 09 02:10 PM
MILLIGAN JOHN FPresident and COOOct 07Sale104.60146,89515,365,818974,048Oct 09 02:10 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Option Exercise23.7631,000736,405153,694Oct 03 02:53 PM
MARTIN JOHN CChairman and CEOOct 01Option Exercise8.01140,6251,125,7034,570,012Oct 03 02:57 PM
MARTIN JOHN CChairman and CEOOct 01Sale105.91140,62514,893,8454,429,387Oct 03 02:57 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Sale105.9833,0003,497,259120,694Oct 03 02:53 PM